Physician profile
Trever Weaver
NPI 1467903674
$2,474.29
in general payments reported to CMS, 2019-2025
21 companies · $742 in 2025
The $742 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $248 · 2023: $210 · 2024: $853 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $880.59 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $358.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $343.94 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $251.36 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $99.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.65 | 2024-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.82 | 2021-2024 | Synjardy, Jardiance |
| Novo Nordisk INC | $68.19 | 2021-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.67 | 2022 | |
| Seqirus USA INC | $33.74 | 2021-2024 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $33.30 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $32.13 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $29.09 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $27.34 | 2022 | |
| Merck Sharp & Dohme LLC | $18.05 | 2025 | Enflonsia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.89 | 2022 | |
| Corium, LLC | $16.78 | 2023 | Adlarity |
| Medtronic, INC. | $13.64 | 2025 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $13.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.32 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.95 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trever Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.